Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 7/20 | 0.70 |
| ▸ | F2 | P00734 | 3/20 | 0.70 |
| ▸ | F10 | P00742 | 3/20 | 0.70 |
| ▸ | F7 | P08709 | 3/20 | 0.70 |
| ▸ | MRGPRX1 | Q96LB2 | 2/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.62 |
| ▸ | F3 | P13726 | 1/20 | 0.62 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.62 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | RXRA | P19793 | 1/20 | 0.57 |
| ▸ | KLK1 | P06870 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10921622 | 0.87 | PRSS1 (0.65) | PRSS1F2F10F7MRGPRX1 | |
| SCHEMBL6940634 | 0.86 | NPC1 (0.65) | PRSS1F2F10F7MRGPRX1 | |
| SCHEMBL4278415 | 0.86 | NPC1 (0.73) | NPC1RAB9AHPGDSMN1; SMN2SMPD1 | |
| SCHEMBL23566116 | 0.84 | PRSS1 (0.65) | PRSS1F2F10F7MRGPRX1 | |
| SCHEMBL22291110 | 0.84 | F10 (0.55) | PRSS1F2F10F7MRGPRX1 | |
| Hydrochloric Acid SCHEMBL23235770 | 0.83 | PRSS1 (0.66) | PRSS1F2F10F7MRGPRX1 | |
| SCHEMBL10927143 | 0.83 | KLK1 (0.61) | PRSS1F2F10F7MRGPRX1 | |
| SCHEMBL242563 | 0.82 | MRGPRX4 (0.77) | NPC1RAB9AHPGDSMN1; SMN2SMPD1 | |
| SCHEMBL27881765 | 0.82 | NPC1 (0.77) | NPC1RAB9AHPGDSMN1; SMN2SMPD1 | |
| SCHEMBL10927771 | 0.81 | PRSS1 (0.53) | PRSS1F2F10F7MRGPRX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663234-A1 | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HIV INFECTIONS | Pfizer Limited (GB) | 2006-06-07 | — | — | EP | disclosed |
| US-20050043300-A1 | Piperazine derivatives | PFIZER INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005016344-A1 | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF HIV INFECTIONS | PFIZER LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043300-A1 | Piperazine derivatives | CD4, CCR5, RRP15 | PRSS1 360/4885F2 963/4885F10 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.